CLINICAL_TRIALS ClinicalTrials.gov record update

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer: a Single-center, Randomized Controlled Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06755684
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:00.539009+00:00
Published At: 2025-01-06T00:00:00+00:00
Record Updated At: 2025-01-06
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["EGFR", "Non-Small Cell Lung Cancer", "Locally Advanced Non-Small Cell Lung Cancer", "Pemetrexed", "Carboplatin", "Bevacizumab", "Antineoplastic Agents", "Tyrosine Kinase Inhibitor"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-01-06"
protocolSection.identificationModule.nctId: "NCT06755684"
protocolSection.identificationModule.officialTitle: "Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer: a Single-center, Randomized Controlled Trial"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.